AZD-3463

• UNSPSC Description:

  AZD-3463 (ALK/IGF1R inhibitor) is an orally active ALK/IGF1R inhibitor, with a Ki of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells[1][2][3].

• Target Antigen:

  Anaplastic lymphoma kinase (ALK); Apoptosis; Autophagy; IGF-1R

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/azd-3463.html

• Solubility:

  DMSO : 20 mg/mL (ultrasonic)

• Smiles:

  ClC(C=NC(NC1=C(OC)C=C(N2CCC(N)CC2)C=C1)=N3)=C3C4=CNC5=C4C=CC=C5

• Molecular Weight:

  448.95

• References & Citations:

  [1]Yongfeng Wang, et al. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep. 2016; 6: 19423.|[2]Sausan A. Moharram, et al. The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer J. 2019 Feb; 9(2): 5.|[3]Ozates NP, et al. Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer. Life Sci. 2021 Jan 1;264:118643.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1356962-20-3